A steady throughput of new agents for the treatment of myeloma

Published on

Email this program

Get Link

At the 20th Congress of the European Hematology Association (EHA), Prof Paul Richardson, of the Dana-Farber Cancer Institute, Boston, MA, talks about the plethora of promising new agents, including proteasome inhibitors, monoclonal antibodies, histone deacetylase (HDAC) inhibitors, that are in clinical development for the treatment of patients with myeloma.

View more programs featuring

Page last updated on January 26, 2016